Second Administrative Task

第二项行政任务

基本信息

  • 批准号:
    8759819
  • 负责人:
  • 金额:
    $ 17.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-09-24 至 2014-09-23
  • 项目状态:
    已结题

项目摘要

This initiative seeks to expeditiously test and analyze novel interventions (i.e., compounds) and their molecular and/or clinical targets for treating clinical dimensions of psychopathology (e.g., social engagement, rigidity or inflexibility) comprising the core features of ASD. Of particular interest are features of ASD as described in the current DSM-IV-TR diagnostic entities, but not typically identified as the primary target of current clinical therapeutics. As described above, there is interest in the study of mechanisms that cut across traditional disorder categories and where relevant mechanisms and clinical targets are assessed directly rather than being inferred through assignment of a particular diagnosis. The NIMH has great interest in studies and clinical trials assessing clinical mechanism and demonstrating target engagement. The outcome of this initiative is expected to lead to enhanced understanding of specific target engagement by such novel interventions, leading to development of innovative treatment approaches for clinical dimensions of psychopathology associated with ASD. In this context, novel interventions (i.e., compounds) may refer either to new chemical entities (NCEs) or to compounds that are being considered for re-purposing from other indications. Testing of compounds that have been FDA-approved for other indications (re-purposing) is of interest if recent basic research discoveries suggest that the compound(s) have the potential to affect a biological mechanism contributing to mental disorders and that has previously been untested in clinical studies. Compounds acting on molecular targets that replicate those of currently marketed psychiatric pharmaceuticals are not of interest for this contract.
该倡议旨在迅速测试和分析新的干预措施(即,化合物)和它们用于治疗精神病理学临床方面的分子和/或临床靶点(例如,社会参与度、刚性或可接受性),其包括ASD的核心特征。特别感兴趣的是ASD的特征,如在当前DSM-IV-TR诊断实体中描述的,但通常不被鉴定为当前临床治疗的主要靶标。如上所述,人们对研究跨越传统疾病类别的机制感兴趣,并且直接评估相关机制和临床靶点,而不是通过指定特定诊断来推断。 NIMH对评估临床机制和证明靶点参与的研究和临床试验非常感兴趣。这一举措的结果预计将导致通过这种新的干预措施加强对特定目标参与的理解,从而为与ASD相关的精神病理学的临床维度开发创新的治疗方法。在这种情况下,新的干预措施(即,化合物)可以指新的化学实体(NCE)或正在考虑从其他适应症中重新利用的化合物。如果最近的基础研究发现表明化合物有可能影响导致精神障碍的生物学机制,并且以前未在临床研究中进行过测试,则对FDA批准用于其他适应症(重新用途)的化合物进行测试是有意义的。本合同对作用于分子靶点的化合物不感兴趣,这些分子靶点与目前市售的精神科药物的分子靶点相似。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

X X其他文献

X X的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('X X', 18)}}的其他基金

01-LOGISTICS FOR NEUROLOGICAL EFFECTS AFTER CHEMICAL NERVE AGENT EXPOSURES NIH WORKSHOP BEING HELD 2/26-27/2014 -- CATALOG # : N/A
01-化学神经毒剂暴露后神经系统影响的物流 NIH 研讨会于 2014 年 2 月 26 日至 27 日举行 -- 目录
  • 批准号:
    8951149
  • 财政年份:
    2014
  • 资助金额:
    $ 17.24万
  • 项目类别:
Development and Maintenance of a Multigenotypic Caloric Restricted Rodent Colony
多基因型热量限制啮齿动物群体的开发和维护
  • 批准号:
    8654993
  • 财政年份:
    2013
  • 资助金额:
    $ 17.24万
  • 项目类别:
IGF::OT::IGF Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of LY
IGF::OT::IGF 双盲、安慰剂对照、概念验证 (POC) LY 试验
  • 批准号:
    8759327
  • 财政年份:
    2013
  • 资助金额:
    $ 17.24万
  • 项目类别:
MGT SVCS/CONTRACT & PROCUREMENT SUP
MGT SVCS/合同
  • 批准号:
    8738841
  • 财政年份:
    2013
  • 资助金额:
    $ 17.24万
  • 项目类别:
FAST-AS - NEW EXPERIMENTAL MEDICINE STUDIES: FAST-FAIL TRIALS IN AUTISM SPECTRUM
FAST-AS - 新的实验医学研究:自闭症谱系的快速失败试验
  • 批准号:
    8741854
  • 财政年份:
    2013
  • 资助金额:
    $ 17.24万
  • 项目类别:
Development and Maintenance of a Multigenotypic Aged Rat Colony
多基因型老年大鼠群体的发育和维持
  • 批准号:
    8745077
  • 财政年份:
    2013
  • 资助金额:
    $ 17.24万
  • 项目类别:
FAST-AS - NEW EXPERIMENTAL MEDICINE STUDIES: FAST-FAIL TRIALS IN AUTISM SPECTRUM
FAST-AS - 新的实验医学研究:自闭症谱系的快速失败试验
  • 批准号:
    8741855
  • 财政年份:
    2013
  • 资助金额:
    $ 17.24万
  • 项目类别:
IGF::OT::IGF Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of Ke
IGF::OT::IGF 双盲、安慰剂对照、概念验证 (POC) Ke 试验
  • 批准号:
    8759330
  • 财政年份:
    2013
  • 资助金额:
    $ 17.24万
  • 项目类别:
PHARMAC L.L.C. (JOHN MCCALL) 100 HOURS AT $150/HOUR FOR CONSULTING SERVICES RELA
PHARMAC 有限责任公司
  • 批准号:
    8564648
  • 财政年份:
    2012
  • 资助金额:
    $ 17.24万
  • 项目类别:
TAS::75 0843::TAS STABILITY TESTING, STORAGE, AND SHIPMENT OF FENOTEROL THERAPEU
TAS::75 0843::TAS 非诺特罗治疗的稳定性测试、储存和运输
  • 批准号:
    8174829
  • 财政年份:
    2010
  • 资助金额:
    $ 17.24万
  • 项目类别:

相似海外基金

Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The impact of changes in social determinants of health on adolescent and young adult mental health during the COVID-19 pandemic: A longitudinal study of the Asenze cohort in South Africa
COVID-19 大流行期间健康社会决定因素的变化对青少年和年轻人心理健康的影响:南非 Asenze 队列的纵向研究
  • 批准号:
    10755168
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
A Priority Setting Partnership to Establish a Patient, Caregiver, and Clinician-identified Research Agenda for Adolescent and Young Adult Cancer in Canada
建立优先合作伙伴关系,以建立患者、护理人员和临床医生确定的加拿大青少年和年轻人癌症研究议程
  • 批准号:
    480840
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
    Miscellaneous Programs
Incidence and Time on Onset of Cardiovascular Risk Factors and Cardiovascular Disease in Adult Survivors of Adolescent and Young Adult Cancer and Association with Exercise
青少年和青年癌症成年幸存者心血管危险因素和心血管疾病的发病率和时间以及与运动的关系
  • 批准号:
    10678157
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
Fertility experiences among ethnically diverse adolescent and young adult cancer survivors: A population-based study
不同种族青少年和年轻成年癌症幸存者的生育经历:一项基于人群的研究
  • 批准号:
    10744412
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
Treatment development for refractory leukemia using childhood/adolescent, and young adult leukemia biobank
利用儿童/青少年和青年白血病生物库开发难治性白血病的治疗方法
  • 批准号:
    23K07305
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular design of Two-Way Player CAR-T cells to overcome disease/antigen heterogeneity of childhood, adolescent, and young adult cancers
双向 CAR-T 细胞的分子设计,以克服儿童、青少年和年轻成人癌症的疾病/抗原异质性
  • 批准号:
    23H02874
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Effects of adolescent social isolation on adult decision making and corticostriatal circuitry
青少年社会隔离对成人决策和皮质纹状体回路的影响
  • 批准号:
    10756652
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
Adolescent trauma produces enduring disruptions in sleep architecture that lead to increased risk for adult mental illness
青少年创伤会对睡眠结构产生持久的破坏,从而导致成人精神疾病的风险增加
  • 批准号:
    10730872
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors
使用量身定制的移动健康策略促进青少年和年轻癌症幸存者的体重管理
  • 批准号:
    10650648
  • 财政年份:
    2023
  • 资助金额:
    $ 17.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了